205 related articles for article (PubMed ID: 33340887)
1. Determining homologous recombination deficiency scores with whole exome sequencing and their association with responses to neoadjuvant chemotherapy in breast cancer.
Kim SJ; Sota Y; Naoi Y; Honma K; Kagara N; Miyake T; Shimoda M; Tanei T; Seno S; Matsuda H; Noguchi S; Shimazu K
Transl Oncol; 2021 Feb; 14(2):100986. PubMed ID: 33340887
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
Imanishi S; Naoi Y; Shimazu K; Shimoda M; Kagara N; Tanei T; Miyake T; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2019 Apr; 174(3):627-637. PubMed ID: 30607631
[TBL] [Abstract][Full Text] [Related]
3. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
4. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
[TBL] [Abstract][Full Text] [Related]
5. Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial.
Zhang L; Wu Z; Li J; Zhu D; Yang L; Shao Y; Lin Y; Liu Z; Cao Y; Zhang G; Shang S; Zhang Y; Wang K
JCO Precis Oncol; 2023 Jan; 7():e2200337. PubMed ID: 36652665
[TBL] [Abstract][Full Text] [Related]
6. Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis.
Chai Y; Chen Y; Zhang D; Wei Y; Li Z; Li Q; Xu B
J Pers Med; 2022 Feb; 12(2):. PubMed ID: 35207810
[TBL] [Abstract][Full Text] [Related]
7. Relationship between homologous recombination deficiency and clinical features of breast cancer based on genomic scar score.
Feng C; Zhang Y; Wu F; Li J; Liu M; Lv W; Li C; Wang W; Tan Q; Xue X; Ma X; Zhang S
Breast; 2023 Jun; 69():392-400. PubMed ID: 37116400
[TBL] [Abstract][Full Text] [Related]
8. Association between Homologous Recombination Repair Defect Status and Long-Term Prognosis of Early HER2-Low Breast Cancer: A Retrospective Cohort Study.
Chen J; Zhu Y; Wu W; Xu Y; Yang W; Ling L; Lin Q; Jia S; Xia Y; Liu Z; Yang Y; Gong C
Oncologist; 2024 Feb; ():. PubMed ID: 38366907
[TBL] [Abstract][Full Text] [Related]
9. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
[TBL] [Abstract][Full Text] [Related]
10. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Telli ML; Timms KM; Reid J; Hennessy B; Mills GB; Jensen KC; Szallasi Z; Barry WT; Winer EP; Tung NM; Isakoff SJ; Ryan PD; Greene-Colozzi A; Gutin A; Sangale Z; Iliev D; Neff C; Abkevich V; Jones JT; Lanchbury JS; Hartman AR; Garber JE; Ford JM; Silver DP; Richardson AL
Clin Cancer Res; 2016 Aug; 22(15):3764-73. PubMed ID: 26957554
[TBL] [Abstract][Full Text] [Related]
11. Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD).
Menzel M; Endris V; Schwab C; Kluck K; Neumann O; Beck S; Ball M; Schaaf C; Fröhling S; Lichtner P; Schirmacher P; Kazdal D; Stenzinger A; Budczies J
Transl Oncol; 2023 Sep; 35():101706. PubMed ID: 37327584
[TBL] [Abstract][Full Text] [Related]
12. Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
Takamatsu S; Brown JB; Yamaguchi K; Hamanishi J; Yamanoi K; Takaya H; Kaneyasu T; Mori S; Mandai M; Matsumura N
JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34423229
[TBL] [Abstract][Full Text] [Related]
13. Homologous Recombination Abnormalities Associated With
Albitar M; Zhang H; Pecora A; Waintraub S; Graham D; Hellmann M; McNamara D; Charifa A; De Dios I; Ma W; Goy A
Breast Cancer (Auckl); 2023; 17():11782234231198979. PubMed ID: 37789896
[TBL] [Abstract][Full Text] [Related]
14. Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis.
Zhang L; Chen Y; Cheng MY; Zhuang X; Zou J; Wei D; Lin YY; Zhang Y; Wang K
Ther Adv Med Oncol; 2022; 14():17588359221096253. PubMed ID: 35547093
[TBL] [Abstract][Full Text] [Related]
15. Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer.
Liao G; Jiang Z; Yang Y; Zhang C; Jiang M; Zhu J; Xu L; Xie A; Yan M; Zhang Y; Xiao Y; Li X
BMC Med; 2021 Sep; 19(1):190. PubMed ID: 34465315
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
Fasching PA; Link T; Hauke J; Seither F; Jackisch C; Klare P; Schmatloch S; Hanusch C; Huober J; Stefek A; Seiler S; Schmitt WD; Uleer C; Doering G; Rhiem K; Schneeweiss A; Engels K; Denkert C; Schmutzler RK; Hahnen E; Untch M; Burchardi N; Blohmer JU; Loibl S;
Ann Oncol; 2021 Jan; 32(1):49-57. PubMed ID: 33098995
[TBL] [Abstract][Full Text] [Related]
17. Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas.
Manié E; Popova T; Battistella A; Tarabeux J; Caux-Moncoutier V; Golmard L; Smith NK; Mueller CR; Mariani O; Sigal-Zafrani B; Dubois T; Vincent-Salomon A; Houdayer C; Stoppa-Lyonnet D; Stern MH
Int J Cancer; 2016 Feb; 138(4):891-900. PubMed ID: 26317927
[TBL] [Abstract][Full Text] [Related]
18. Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.
Ballot E; Galland L; Mananet H; Boidot R; Arnould L; Desmoulins I; Mayeur D; Kaderbhai C; Ilie S; Hennequin A; Bergeron A; Derangère V; Ghiringhelli F; Truntzer C; Ladoire S
Breast Cancer Res; 2022 Nov; 24(1):80. PubMed ID: 36401316
[TBL] [Abstract][Full Text] [Related]
19. Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
Takamatsu S; Brown JB; Yamaguchi K; Hamanishi J; Yamanoi K; Takaya H; Kaneyasu T; Mori S; Mandai M; Matsumura N
JCO Precis Oncol; 2022 May; 6():e2200085. PubMed ID: 35613413
[TBL] [Abstract][Full Text] [Related]
20. A Multiomics Signature Highlights Alterations Underlying Homologous Recombination Deficiency in Triple-Negative Breast Cancer.
Su GH; Jiang L; Xiao Y; Zheng RC; Wang H; Jiang YZ; Peng WJ; Shao ZM; Gu YJ; You C
Ann Surg Oncol; 2022 Oct; 29(11):7165-7175. PubMed ID: 35711018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]